Wayne C Koff

USPTO Granted Patents = 25 (Patent Applications = 3)

CIPO Patents = 2

EPO Patents = 8 (Patent Applications = 12)

Average Co-Inventor Count = 5.9

ph-index = 5

Forward Citations = 72(Granted Patents)

Location History:

Stony Brook, NJ (US) (2003)
New York, NY (US) (2018 - 2022)
Stony Brook, NY (US) (2012 - 2024)

Company Filing History:

24 out of 68

International Aids Vaccine Initiative

patents

19 out of 1,186

The Scripps Research Institute

patents

14 out of 28

Theraclone Sciences, Inc.

National Institutes of Health, a Component of the US Dept. of Health & Human Services

patents

6. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2003-2025

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410243 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2025-09-09),

2. 12312396 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2025-05-27),

3. RE50268 - Broadly neutralizing antibody and uses thereof (2025-01-14),

4. 12018067 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2024-06-25),

5. 11845789 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2023-12-19),

6. 11584789 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2023-02-21),

7. 11319362 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies (2022-05-03),

8. RE49037 - Broadly neutralizing antibody and uses thereof (2022-04-18),

9. 10894080 - Transgenic VERO-CD4/CCR5 cell line (2021-01-19),

10. 10865234 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2020-12-15),

11. 10836811 - Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody (2020-11-17),

12. 10407493 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2019-09-10),

13. 10279027 - Transgenic Vero-CD4/CCR5 cell line (2019-05-07),

14. 10239934 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity (2019-03-26),

15. 10093720 - Broadly neutralizing antibody and uses thereof (2018-10-09),

Title: Inventor Wayne C Koff - Revolutionizing the World of Biotechnology

Introduction: Wayne C Koff, a distinguished inventor hailing from New York, NY, has made significant contributions to the field of biotechnology through his innovative creations and groundbreaking patents.

Latest Patents: Wayne C Koff's latest patents include cutting-edge technologies in vaccine development, genetic engineering, and drug delivery systems, showcasing his commitment to advancing healthcare solutions for global challenges.

Career Highlights: With a career spanning over two decades, Wayne C Koff has held key positions in renowned biotech companies and research institutions, leading teams to develop life-saving innovations that have reshaped the industry.

Collaborations: Throughout his career, Wayne C Koff has collaborated with top scientists, researchers, and pharmaceutical companies worldwide, fostering a culture of innovation and knowledge-sharing to drive progress in biotechnology.

Conclusion: Wayne C Koff's passion for pushing the boundaries of biotechnology, coupled with his relentless pursuit of excellence, solidifies his position as a visionary inventor whose work continues to impact the world positively.

This text is generated by artificial intelligence and may not be accurate.